699855 | 3D-(6-acyl) PHAD®

Monophosphoryl Hexa-acyl Lipid A, 3-Deacyl (Synthetic)


Powder

Size SKU Packaging Price
1mg 699855P-1mg 699855P-1mg $184.00
5mg 699855P-5mg 699855P-5mg $735.00
Base Price: ${originalprice|money}
Custom Packaging: (${concentration} @$4.00/ea. + $100) ${custompackagingtotal|money}
Packaging: ${concentration}
Item Total: ${totalprice|money}
Please select an option above.
${sku} - ${concentration}

3D-(6-acyl) PHAD®

3D-(6-acyl) PHAD®

Monophosphoryl Hexa-acyl Lipid A, 3-Deacyl (Synthetic)

Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization. Because vaccine adjuvants using Lipid A have proven to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD®), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.

Adjuvant Activity

Antigen: gp140 from HIV-1

PHAD®, 3D-PHAD®, and 3D(6A)-PHAD® have been tested extensively in animals using a variety of antigens. In all cases, these adjuvants exhibit a similar activity and safety profile to bacterially-derived MPL. The data above demonstrate the equivalency of the three synthetic adjuvants to the bacterially-derived MPL when presented in a liposomal carrier system (DMPC/DMPG/Cholesterol).

Hygroscopic
No
Light Sensitive
No
Molecular Formula
C96H184N3O21P
Percent Composition
C 65.98%, H 10.61%, N 2.40%, O 19.23%, P 1.77%
Purity
>99%
Stability
1 year
Storage Temperature
-20°C
Molecular Weight
1747.469
Exact Mass
1746.316